Everest Medicines gets China NMPA approval for CARDAMYST® in PSVT
Everest Medicines announced China’s NMPA approval of CARDAMYST® for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Shanghai, Sept. 3, 2026 — Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, said China’s National Medical Products Administration approved CARDAMYST® in PSVT.